Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2026 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
A new vaccine to immunize against Simian Immunodeficiency Virus (SIV), a virus that appears in African primates and is similar to HIV, has proven to be effective in about half of its test subjects who were later exposed to the virus, according to a new study published in the journal Nature. Oregon Health & Science University's Louis Picker, M.D., made the breakthrough after a decade of developing an SIV vaccine as a means to discover an HIV vaccine. The researchers tested their vaccine in rhesus macaque monkeys at the Oregon National Primate Research Center, according to the university. Of the monkeys who were vaccinated and then exposed to SIV, more than half were found to be uninfected and, after eight years, most of the monkeys' immune systems were able to maintain control of the virus. However, the unvaccinated animals that were exposed to the virus developed simian AIDS. Researchers have chosen the cytomegalovirus, or CMV, as the delivery system, or vector, for the vaccine. CMV is a benign virus to those without compromised immune systems. Related to the herpes virus, most adults are infected with CMV (between 50% and 80% of the adult population of the United States), and it may remain in the body for life. The vaccine it carries would build and maintain a resistance against HIV by programming certain T-cells to remain on constant patrol for the virus. Picker said that while the results of the study are groundbreaking, it would take years before scientists are testing for the vaccine in humans. 'Imagine if you're looking at a very high, seemingly unscaleable cliff,' he said. 'And so far efforts to climb it have not reached the top. What this work basically does is show a path. We still have to climb the cliff, but we now have a path, which we can follow. We have a response that we know that's protective of a highly aggressive virus that is similar to HIV, and we have a vector that generates those responses, so it should translate, but we still have to put on the climbing gear, and climb the path.'
From our Sponsors
Most Popular
Plus: Featured Video
Latest Stories
How to find an HIV-competent healthcare provider, according to advocates
May 19 2026 4:55 PM
Can a single infusion of immune cells suppress HIV for years?
May 11 2026 11:39 AM
Newly diagnosed with HIV? Advocates share their best advice for seeking treatment
April 29 2026 3:32 PM
National HIV advocacy group's CEO rejects claims of crisis
April 21 2026 5:14 PM
Beyond awareness: How youth leadership is reshaping the HIV response
April 10 2026 9:12 AM
Saving public health? AIDS United's new CEO has a plan
March 23 2026 9:48 AM
Struggling with daily HIV meds? Monthly shots may be the answer
March 20 2026 7:12 AM
Did you know over half of HIV-positive people in the world are female?
March 09 2026 6:47 PM
Why are Black people still the most affected by HIV criminalization?
February 27 2026 8:44 PM
What to know about HIV testing and treatment if you’re Black and LGBTQ+
February 24 2026 9:04 AM
6 Black activists who changed the HIV/AIDS response in America
February 09 2026 9:55 AM
National Black HIV/AIDS Awareness Day: a time for action on many fronts
February 07 2026 3:49 PM
Black Americans are disproportionately criminalized for living with HIV. Here's how
February 06 2026 4:26 PM
13 Black community organizations fighting HIV in the U.S. you should know
February 03 2026 10:45 AM
Meet the activist who wants people living with HIV to know they’re still sexy
January 28 2026 10:02 AM
An HIV breakthrough is here. Let's not let it go to waste
January 21 2026 12:40 PM
HIV-positive men stage 'Kiss-In' protest at U.S.-Mexico border
December 01 2025 12:56 PM






























































